SATB1 siRNA-encapsulated immunoliposomes conjugated with CD44 antibodies target and eliminate gastric cancer-initiating cells
| Autor: | Guoen Fang, Haijia Li, Jie Gao, Xuchao Xue, Zhi Zheng, Luming Zheng, Jianmin Qin, Feng Yang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
OncoTargets and Therapy Metastasis 03 medical and health sciences 0302 clinical medicine medicine Cytotoxic T cell Pharmacology (medical) biology business.industry Stomach digestive oral and skin physiology CD44 Cancer SATB1 medicine.disease digestive system diseases In vitro 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis biology.protein Cancer research Antibody business |
| Zdroj: | OncoTargets and Therapy. |
| ISSN: | 1178-6930 |
| Popis: | Feng Yang,1 Zhi Zheng,1 Luming Zheng,2 Jianmin Qin,1 Haijia Li,1 Xuchao Xue,3 Jie Gao,4 Guoen Fang3 1Department of General Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 201805, People’s Republic of China; 2Department of General Surgery, General Hospital of Jinan Military Area, Jinan 250031, People’s Republic of China; 3Department of General Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, People’s Republic of China; 4Department of Pharmaceutical Science, College of Pharmacy, Second Military Medical University, Shanghai 200433, People’s Republic of China Purpose: Gastric cancer, the cancer initiated from the stomach, is ranked as the third most frequent reason of cancer death worldwide. Gastric cancer-initiating cells (CICs) are one of the crucial causes for the metastasis and recurrence of gastric cancer, and CD44 is considered to be one marker for gastric CICs. Special AT-rich sequence binding protein 1 (SATB1) is a protein that promotes cancer progression, metastasis, and invasion and also participates in the maintenance of CICs. In this study, we investigated the therapeutic effect of SATB1 siRNA against gastric CICs and we constructed SATB1 siRNA-encapsulated immunoliposomes conjugated with CD44 antibodies (CD44-SATB1-ILs) to enhance the therapeutic effect of SATB1 siRNA against gastric CICs. Methods: We investigated the therapeutic effect of the SATB1 suppression by SATB1 siRNA on CD44+ gastric CICs. CD44-SATB1-ILs were developed by the lyophilization/hydration approach. The targeting and cytotoxic effect of CD44-SATB1-ILs toward gastric CICs were evaluated in vitro. Results: In this study, for the first time, we confirmed that SATB1 suppression by SATB1 siRNA preferentially eliminated CD44+ gastric CICs. The results showed that CD44-SATB1-ILs could efficiently and specifically promote the SATB1 siRNA delivery to CD44+ gastric CICs, achieving superior therapeutic effects against CD44+ gastric CICs than non-targeted liposomes. Conclusion: As far as we know, our report is the first research that indicated the promotion of siRNA delivery via nanoparticles to gastric CICs and achievement of superior therapeutic effect against gastric CICs by utilization of CD44 antibody. Therefore, CD44-SATB1-ILs represent an up-and-coming approach for eliminating gastric CICs and also a promising treatment for therapy of gastric cancer. Keywords: gastric cancer, SATB1, cancer-initiating cells, immunoliposomes, CD44 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|